1. < Blood Cancers & Disorders
Profile picture for eferret

Summary of 2025 meeting of American Society of Hematologists

Posted by eferret @eferret, 23 hours ago

The meeting reported on new developments in JAK2 inhibitors and the
shift to tracking the allele burden in addition to tracking just hematocrit.
https://mailchi.mp/e3b49744f1a5/new-developments-in-mpn-research-10612935

Interested in more discussions like this? Go to the Blood Cancers & Disorders Support Group.

Profile picture for janemc
janemc | @janemc | 5 hours ago

Thank you for providing this link!

Just one fascinating excerpt:

********************
Mutant CALR Antibody (INCA033989) Hits Major Milestones
Summary: Incyte’s first-in-class monoclonal antibody targeting mutant CALR was a star of the 2025 conference. New Phase 1/2 data showed that the drug is "remarkably clean," meaning it shows almost zero off-target toxicity.

Outcome: In ET patients, the antibody rapidly normalized platelet counts. In MF patients, it showed good results by reducing spleen size and improving anemia, demonstrating that directly targeting the CALR mutation is an effective and strong approach.

Why it matters: This breakthrough is a massive win for the CALR-mutated community. If you have a CALR mutation, your disease now has its own "bespoke" treatment. This therapy doesn't just manage the disease; it hunts the mutated cells specifically, which could eventually lead to a much deeper and more durable response than anything currently on the market.

*****************

Click the link to learn more!!

REPLY
1 reply
Profile picture for nohrt4me (Jean)
nohrt4me (Jean) | @nohrt4me | 3 hours ago
In reply to @janemc "Thank you for providing this link! Just one fascinating excerpt: ******************** Mutant CALR Antibody (INCA033989) Hits..." + (show)
Profile picture for janemc @janemc

Thank you for providing this link!

Just one fascinating excerpt:

********************
Mutant CALR Antibody (INCA033989) Hits Major Milestones
Summary: Incyte’s first-in-class monoclonal antibody targeting mutant CALR was a star of the 2025 conference. New Phase 1/2 data showed that the drug is "remarkably clean," meaning it shows almost zero off-target toxicity.

Outcome: In ET patients, the antibody rapidly normalized platelet counts. In MF patients, it showed good results by reducing spleen size and improving anemia, demonstrating that directly targeting the CALR mutation is an effective and strong approach.

Why it matters: This breakthrough is a massive win for the CALR-mutated community. If you have a CALR mutation, your disease now has its own "bespoke" treatment. This therapy doesn't just manage the disease; it hunts the mutated cells specifically, which could eventually lead to a much deeper and more durable response than anything currently on the market.

*****************

Click the link to learn more!!

Jump to this post

@janemc You beat me to it! Not sure where this is in testing, and my guess is that you will need to own a gold mine to pay for it, but this is excellent news for young ET and MF patients and anyone who is approaching that 20-year mark on HU or is having trouble with it!

REPLY
Profile picture for janemc
janemc | @janemc | 1 hour ago

Even if we were all zillionaires, this probably won't be available in our lifetimes.

But I welcome any and all news of progress!

REPLY
Please sign in or register to post a reply.